Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
Status:
RECRUITING
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
This is an open label, phase 1 study for AML subjects with relapsed or refractory disease or subjects in morphologic remission with MRD+ after first line therapy with venetoclax+HMA. A preliminary dose-finding cohort will be followed by 3 expansion cohorts.